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Two features characterize the pathogenesis of second-Heterogeneous expression of receptor mRNAs in parathyroid
ary hyperparathyroidism (HPT). The first is an inadequateglands of secondary hyperparathyroidism.
Background. Secondary hyperparathyroidism (HPT) is char- control of secretion of parathyroid hormone (PTH) from
acterized by inappropriate control of parathyroid hormone (PTH) the parathyroid cells, and the second is an increased rate
secretion and asymmetric hyperplasia of the parathyroid glands. of parathyroid cell proliferation. While the regulation ofReceptors for calcium and vitamin D are involved in the control
secretion has been extensively studied [1], parathyroidof secretion, as well as parathyroid cell proliferation. Defective
proliferation and the factors influencing this process arereceptor mechanisms therefore may play a role in the pathogen-
ensis of secondary HPT. Previous studies have shown that the less well understood. Calcium and active vitamin D and
expression of calcium receptor (CaR), calcium-sensing recep- their receptors are involved in both processes.
tor (CAS) and vitamin D receptor (VDR) protein, and mRNA Calcium regulates PTH secretion via receptors in the
is decreased in hyperplastic parathyroid glands of secondary
cell membrane. The best established calcium receptor isHPT when compared with normal parathyroid glands.
the seven-transmembrane receptor, CaR [2–5]. AnotherMethods. Thirty-six hyperplastic glands from 18 patients with
secondary hyperparathyroidism were analyzed with in situ hy- possible calcium-sensing receptor is the large protein
bridization in order to investigate the expression of CaR, CAS, gp330 or CAS, a member of the low density lipoprotein
VDR, and PTH mRNAs in the same specimens. In nine nodular (LDL)-receptor superfamily [6–10]. Studies on the secre-
parathyroid glands, it was possible to make a comparison be-
tion of PTH from parathyroid cells of secondary HPTtween the expression of these mRNAs in nodular and inter-
in vitro have demonstrated a shift in set point, wherenodular areas.
the PTH secretion is inappropriately high in relationshipResults. The level of CaR was in the same order of magni-
tude in the hyperplastic glands and in the biopsies of normal to the extracellular calcium level [11]. One reason for a
parathyroid, whereas the levels of CAS, VDR and PTH were shift in set point could be inactivating mutations in CaR.
clearly reduced in the hyperplastic glands. There was a positive However, such mutations have only been demonstratedcorrelation between the expression of CaR and CAS (P 
in familial hypocalciuric hypercalcemia, and not in pri-0.02). Otherwise, no correlations between CaR, CAS, VDR,
mary or secondary HPT [4]. An alternative explanationand PTH mRNAs were found. The expression of all four genes
was highly variable as well between different glands as within for the shift in set point would be a decreased number
individual glands. of receptors in the parathyroid cells. Previous studies
Conclusion. The expression of mRNAs for receptors of im- have shown reduced expression of CaR mRNA and pro-
portance in the control of PTH secretion and parathyroid cell
tein both in adenomas from patients with primary HPTproliferation is heterogeneously decreased in parathyroid glands
and in hyperplastic parathyroid glands from patients withof secondary HPT. The expression pattern corroborates earlier
studies in which it has been assumed that each nodule in sec- secondary HPT [12–14]. A reduced expression of CAS
ondary HPT is of monoclonal origin, but that the monoclonal has been demonstrated in the enlarged glands of second-
origin of each nodule is independent. ary HPT [15]. The reduction in CAS has been shown to
parallel the increase in set point for PTH secretion, and
antibodies directed against CAS block the response to
Key words: calcium receptor, calcium-sensing receptor, vitamin D re-
extracellular calcium in vitro [7]. Although many findingsceptor, monoclonal nodules, hyperplastic parathyroid glands, secreted
PTH, cell proliferation. have suggested a role for CAS in the regulation of PTH
secretion, definitive proof has been difficult to obtain
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Calcium has an effect not only on PTH secretion, but
also on transcription of the PTH gene mediated via cal-
cium response elements in the upstream flanking region
of the PTH gene [16–18].
The role of CaR and CAS in parathyroid cell prolifera-
tion is less well understood. However, calcium also seems
to have a direct effect on proliferation, and this effect
is probably mediated via calcium receptors on the cell
surface.
The relative importance of calcium in relation to vita-
min D is difficult to determine. Vitamin D inhibits tran-
scription of the PTH gene via an intranuclear receptor
protein, the vitamin D receptor (VDR) [19, 20]. In this
manner, vitamin D also influences PTH secretion. Vita-
min D inhibits parathyroid cell proliferation [21], whereas
the combination of low calcium and low vitamin D stimu-
lates parathyroid cell proliferation [22]. Several studies
have demonstrated reduced levels of VDR in hyperplas-
tic parathyroid glands of secondary HPT [23–25]. The
most prominent decrease was seen in the largest glands
and particularly in nodular hyperplasia [26].
Intermittent intravenous 1,25(OH)2D3 therapy is tradi-
tionally used in patients with secondary HPT to suppress
PTH secretion [27] and diminish hyperplasia [28]. For un-
known reasons, some patients develop unresponsiveness
to this treatment. This resistance is thought to be caused
at least in part by the reduced VDR density of the para-
thyroid glands.
It is hypothesized that parathyroid cells initially prolif-
erate polyclonally. Diffuse hyperplasia is then followed
by monoclonal proliferation of certain cells within the
diffuse hyperplasia resulting in nodular hyperplasia [29].
Nodular hyperplasia is considered to be present in more
severe secondary hyperparathyroidism. In line with this
is the fact that transplantation of nodular parathyroid
tissue to the forearm as part of surgical treatment of sec-
ondary HPT results in fewer good results than transplanta-
tion of diffusely hyperplastic parathyroid tissue [30].
Until the recent publication by Yano et al on the associ-
ation between decreased CaR expression and prolifera-
tion of parathyroid cells in secondary HPT [31], there
has been no report analyzing the relationship between
CaR and VDR in the same specimens. We have studied
the mRNA expression of CaR, CAS, VDR, and PTH in
a large number of hyperplastic glands from patients with
secondary HPT, and demonstrate a highly variable ex-
pression of these mRNAs that is apparently independent
of each other. It seems as if each clone of parathyroid
cells has its own expression pattern, a finding that may
explain the variable clinical course of secondary HPT.
METHODS
Patient material
The study includes a total of 36 hyperplastic parathy-
roid glands from 18 patients operated on for secondary
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HPT at the Karolinska Hospital (Tables 1 and 2). Fifteen
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Table 2. Weight and histopathological diagnosis of the hyperplastic glands from the 18 patients in the study
Patient Gland Gland weight
no. no. mg Histopathology Analyzed part of the frozen section
1 1 2200 Nod. hyperplasia, chief  oxyphil cell One nodule and parenchyma outside nodule
2 560 Nod. hyperplasia, chief  oxyphil cell Three nodules and intermodular parenchyma
3 645 Nod. hyperplasia, chief  oxyphil cell Two nodules and intermodular parenchyma
4 370 Nod. hyperplasia, chief  oxyphil cell NA
2 1 906 Nod. hyperplasia, chief  water clear cell NA
2 150 Diff. hyperplasia, chief cell Whole section
3 1 271 Nod. hyperplasia (slight), oxyphil  transitional NA
2 740 Diff. hyperplasia, chief cell Whole section
3 39 Diff. hyperplasia, chief cell NA
4 nk Diff. hyperplasia, chief cell NA
4 1 1007 Nod. hyperplasia, chief cell NA
2 310 Diff. hyperplasia, chief cell Whole section
3 1267 Diff. hyperplasia, chief cell NA
4 60 Diff. hyperplasia, chief cell NA
5 1 500 Nod. hyperplasia, chief cell One nodule and parenchyma outside nodule
2 796 Nod. hyperplasia (slight), chief cell Whole section
3 410 Diff. hyperplasia, chief cell NA
6 1 1167 Nod. hyperplasia, oxyphil cell Whole section
2 515 Nod. hyperplasia, chief  oxyphil cell Whole section
3 1100 Nod. hyperplasia, oxyphil cell NA
4 640 Nod. hyperplasia, chief cell NA
7 1 1150 Nod. hyperplasia, chief  oxyphil cell One nodule and parenchyma outside nodule
2 1570 Nod. hyperplasia, chief  oxyphil cell Whole section
3 1500 Nod. hyperplasia, chief  oxyphil cell Whole section
4 1200 Nod. hyperplasia, chief  oxyphil cell One nodule and parenchyma outside nodule
8 1 150 Nod. hyperplasia (slight), chief cell Whole section
2 100 Diff. hyperplasia, chief cell NA
3 100 Nod. hyperplasia, chief cell Whole section
4 180 Nod. hyperplasia, chief cell Whole section
9 1 95 Diff. hyperplasia, chief cell Whole section
2 800 Nod. hyperplasia, chief  oxyphil cell One nodule and parenchyma outside nodule
3 216 Nod. hyperplasia, chief cell One nodule and parenchyma outside nodule
4 550 Nod. hyperplasia, chief cell One nodule and parenchyma outside nodule
10 1 230 Diff. hyperplasia, chief cell NA
2 938 Nod. hyperplasia, chief  oxyphil cell Whole section
3 173 Nod. hyperplasia (slight), chief cell NA
4 70 Nod. hyperplasia (slight), chief  oxyphil cell NA
11 1 1057 Nod. hyperlasia, chief  oxyphil cell Whole section
2 606 Nod. hyperlasia, chief  oxyphil cell Whole section
3 546 Nod. hyperlasia, chief  oxyphil cell Whole section
4 2370 Nod. hyperlasia, chief  oxyphil cell Whole section
12 1 800 Diff. hyperplasia, chief cell  oxyphil NA
2 2620 Diff. hyperplasia, chief cell Whole section
3 1735 Diff. hyperplasia, chief cell  oxyphil NA
4 1718 Diff. hyperplasia, oxyphil Whole section
13 1 3077 Nod. hyperplasia, chief  oxyphil cell Two nodules
2 100 Nod. hyperplasia, oxyphil cell Whole section
3 652 Nod. hyperplasia, chief  oxyphil cell Whole section
4 1155 Nod. hyperplasia, chief  oxyphil cell NA
14 1 2250 Diff. hyperplasia, chief cell NA
2 740 Nod. hyperplasia, chief cell NA
3 140 Nod. hyperplasia, chief cell NA
4 170 Nod. hyperplasia, oxyphil cell One nodule and parenchyma outside nodule
15 1 513 Nod. hyperplasia, chief  oxyphil cell Whole section
2 450 Nod. hyperplasia, chief  oxyphil cell NA
16 1 703 Nod. hyperplasia, transitional cell Whole section
2 146 Nod. hyperplasia, chief cell NA
3 647 Nod. hyperplasia, chief cell NA
17 1 370 Nod. hyperplasia, oxyphil cell Whole section
2 nk Nod. hyperplasia, chief  oxyphil cell NA
3 190 Nod. hyperplasia, chief cell NA
18 1 1009 Diff. hyperplasia, chief cell Whole section
2 1440 Diff. hyperplasia, chief cell NA
3 nk Diff. hyperplasia, chief cell NA
4 nk Nod. hyperplasia (slight), chief cell NA
Abbreviations are: NA, not analyzed; nk, not known; diff., diffuse; nod., nodular.
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patients had advanced chronic renal failure. One was with [35S]deoxyATP (NEN, Life Science Products, Bos-
admitted with acute renal failure. One had a renal failure ton, MA, USA) using terminal deoxynucleotidyl trans-
of not-yet-diagnosed reason, and one had hypophos- ferase (Amersham Pharmacia Biotech, Piscataway, NJ,
phatemic rickets with normal serum creatinine. At the USA) followed by a purification step using the QIAquick
time of their operation, 11 patients were receiving hemo- nucleotide removal kit (Qiagen, Hilden, Germany).
dialysis. Two were receiving peritoneal dialysis, and two Consecutive cryostat sections of hyperplastic parathy-
had functioning renal transplants. All patients were hyper- roids and normal biopsies were cut and thaw-mounted
calcemic with a median preoperative albumin corrected onto SuperFrostPlus (Menzel-Gla¨ser, Hannover, Ger-
serum calcium concentration of 2.83 mmol/L (range 2.58 many) slides. Hybridization was then performed essen-
to 3.11) and a median preoperative serum intact PTH tially as described by Dagerlind et al [32]. The hybridiza-
of 288 ng/L (range 83 to 1860). Median serum phosphate tion solution containing the labeled probe was spread
was 1.55 mmol/L (range 0.60 to 2.90). Median total out on the sections, and the slides were then covered
weight of the parathyroids removed in each patient was with parafilm, placed in a humified box, and incubated
2078 mg. The median weight of the individual glands overnight at 42C. After hybridization, the sections were
analyzed with in situ hybridization was 648 mg (range 95 sequentially rinsed in five changes of 1  SSC at 60C
to 3077 mg). The histopathological investigation showed for 60 minutes, put on the bench for one hour to cool,
diffuse hyperplasia of all glands in one patient, nodular and then rinsed in distilled water and dehydrated in 70,
hyperplasia in seven patients, and a mixed pattern of 95, and 99% ethanol. After air drying, the sections were
diffuse as well as nodular hyperplasia in ten patients. A exposed to Hyperfilm beta-max x-ray film (Amersham,
total of 29 glands showing nodular hyperplasia and seven CEA AB, Uppsala, Sweden) for seven days. Eight stan-
glands showing diffuse hyperplasia were analyzed. dards (Amersham International, Buckingshamshire, UK)
Fifteen patients had received treatment with vitamin to construct a gray level as a function of the activity
D, either 1(OH)D3 or 1,25(OH)2D3. In nine cases, the concentration were included. The x-ray films were then
treatment was intermittent intravenous and in four cases developed, and the semiquantification of film autoradio-
oral. Two patients had received both intravenous and
grams was carried out. Gray levels corresponding to the
oral treatment during the course of the disease. In most
eight standards were determined, and the analysis wascases, this treatment was not given during the last three
made using the NIH Image program (developed at theweeks before the operation due to hypercalcemia. How-
U.S. National Institutes of Health and available on theever, in four cases, treatment was stopped only a few
internet at http://rsb.info.nih.gov/nih-image/). Care wasdays before the surgery (Table 1).
taken to get the optimal gray scale and to exclude fat cells,Biopsies of normal parathyroid tissue from three pa-
connective tissue, and vessels when measuring. Only ho-tients operated on for sporadic primary hyperparathy-
mogenous areas consisting of parathyroid parenchymalroidism were analyzed for comparison.
cells were measured. This procedure has been shown toThe tumors and biopsies were snap frozen in liquid
be reasonably reproducible with a variation coefficientnitrogen after removal and stored at 70C until analy-
of 14% [13]. In nodular parathyroids, nodules and in-sis. The study was approved by the local ethics committee
ternodular areas were measured separately (Table 2).of the Karolinska Hospital.
Only nodules that could be identified in most analyzed
mRNA in situ hybridization sections (that is, mainly large nodules) were selected for
measurement.The cellular expression of mRNA was studied using
in situ hybridization. Oligonucleotide probes with se-
Statistical analysesquences complementary to mRNAs encoding for VDR
Statistical analysis was performed using the StatView(nt 1257–1296; GenBank accession number J03258.1),
4.02 software. An analysis of variance table was used toCaR (nt 1371–1410, GenBank/EMBL Data Bank acces-
evaluate correlations between variables. Comparisonssion number U20759 and U20760), CAS (nt 666–705,
GenBank/ EMBL Data Bank accession number S73145) between nodules and internodular areas from the same
and for PTH (nt 402–432, GenBank accession number glands were made using the Wilcoxon signed-rank test.
J00301.1) were synthesized. To verify the presence of P values 0.05 were considered significant.
mRNA an oligonucleotide complementary to GAPDH
(nt 1149–1193; GenBank/EMBL Data Bank accession
RESULTSnumber M33197), mRNA was also synthesized. Also, a
Thirty-six hyperplastic parathyroid glands from 18 pa-sense probe (corresponding to the inverted sequence
tients with hypercalcemic secondary HPT were analyzedbetween nt 2504 and 2545 of IgF2; EMBL Data Bank
with in situ hybridization for expression of GAPDH,accession number X03562.1) was included as a negative
control. The oligonucleotides were labeled at the 3	 end CaR, CAS, VDR, and PTH mRNAs. The clinical infor-
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Fig. 1. (A) Autoradiogram of consecutive sec-
tions of three glands from patient 1 and nor-
mal biopsies (upper row only). Frozen sections
were hybridized with oligonucleotide probes
complementary to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), calcium receptor
(CaR), calcium-sensing receptor (CAS), vita-
min D receptor (VDR), and parathyroid hor-
mone (PTH) mRNA, and then exposed to
x-ray film. Nodular areas are denoted N1 to
N6 and internodular areas I1 to I3. A highly
variable expression of all mRNAs is shown.
mation for each case and gland is detailed in Tables 1 relation was found. A positive correlation was found
between the expression of CaR and CAS mRNA (P and 2.
0.02; Fig. 3). Otherwise, no correlations between CaR,
Overview of expression levels CAS, VDR, and PTH mRNAs were found. When all
measured areas in the nodular glands were compared withNo signal was detected with the sense probe in any
tissue analyzed, supporting the specificity of the results glands exhibiting diffuse hyperplasia, no difference was
seen with regard to any of the analyzed mRNAs. Thereobtained with the antisense probes. Since all glands in-
vestigated were positive for GAPDH, no specimen was was a positive correlation between tumor weight and the
“average expression” of CaR mRNA in nodular hyper-excluded from analysis due to suspicion of increased
degradation of mRNA due to RNAse activity. plasia (P  0.01). “Average expression” was estimated
by calculation of the mean of the expression in measuredA great variability was seen in the expression of the
different mRNAs, not only between, but also within the areas in a single gland, irrespective of the size of those
areas. Otherwise, no correlations between tumor weightanalyzed hyperplastic glands (Fig. 1A). The mean levels
of GAPDH, CaR, CAS, VDR, and PTH mRNA in all and the expression of different mRNAs were found.
measured areas were 170
 81 (N 42), 290
 225 (N
Expression levels within the individual glands38), 32 
 26 (N  31), 121 
 70 (N  42), and 145 

106 (N  42) nCi/g (mean 
 SD), respectively. When The variable expression within nodular glands is exem-
plified in Figure 1, which shows sections of three glandscompared with the few available biopsies of normal para-
thyroid glands (N  2 to 3) run in the same experiment, from patient 1 and corresponding controls hybridized in
the same experiment and exposed to the same film. Sixthe levels of GAPDH and CaR mRNA were in the same
order of magnitude, whereas the levels of CAS, VDR, nodular areas (N1 to N6) and three internodular areas
(I1 to I3) can be seen in these glands. N1 is an oxyphiland PTH mRNA were lower in the hyperplastic glands
(median 23, 41, and 35%, respectively; Fig. 2). No statisti- nodule, whereas I1 is mainly composed of chief cells. The
three nodules N2 to N4 and the internodular area I2 ofcal evaluation of the relationship between hyperplastic
and normal glands was made due to the low number of gland 2 are all composed of chief cells. I3 of gland 3 consists
of chief cells, whereas N6 is composed of oxyphil cells.controls.
When the expression of GAPDH mRNA was com- GAPDH mRNA is expressed at a higher level in the
nodular than in the internodular areas of glands 1 andpared with the expression of the other mRNAs, measured
in the same defined area of consecutive sections, no cor- 3. No great differences in CaR mRNA can be seen be-
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Fig. 1 (Continued). (B and C) Autoradio-
gram of consecutive sections hybridized with
probes complementary to GAPDH, CaR, CAS,
VDR, and PTH mRNA showing three glands
where the expression of VDR mRNA is high
and of PTH mRNA low (B) and vice versa
(C). In patient 14, a nodule shows high expres-
sion of VDR mRNA (B).
tween the nodular and internodular areas in any gland. Although the anticipated negative relationship be-
tween VDR and PTH mRNAs was observed in a fewThe expression of CAS in this patient was extremely
low. Only a faint expression can be identified in I2. VDR cases (Fig. 1B), the opposite was seen in other cases (Fig.
1C). No significant correlation between VDR and PTHmRNA expression, on the other hand, is highly variable.
All internodular areas of I1 to I3 have a low expression, mRNAs could be demonstrated.
The relationship between nodular and adjacent inter-whereas the nodular parts go from very low levels in N5,
to low in N1, moderate in N3 and N4, and high in N2 modular areas could be analyzed in nine glands. In 12 to
13 such pairs of nodular/internodular areas, the mRNAand N6. The highest expression of PTH mRNA is seen
in the nodular parts of gland 2. In gland 3, the level of expression was higher in the nodular than in the interno-
dular area of 10 out of 13 (GAPDH), 8 of 12 (CaR), 11PTH mRNA in the internodular area I3 is in between
the two nodules N5 an N6. of 12 (VDR), and 11 of 13 (PTH) pairs. The results for
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Fig. 3. Scattergram showing the correlation between the expression of
CaR and CAS mRNA levels.
Fig. 2. Box plot of GAPDH, CaR, VDR and PTH mRNA expression
level in nodular glands that differ from previous resultsin 36 parathyroid tumors from patients with secondary hyperparathy-
roidism in relationship to the percent of normal biopsies. The box mainly at the protein level, but also in some cases at the
represents the 25th to the 75th percentile, and the whiskers represent mRNA level.the 10th and the 90th percentiles. The circles represent single values
Reduced immunostaining for CaR protein has beenoutside the 10th and 90th percentiles.
demonstrated in primary as well as secondary HPT. Kifor
et al reported that the staining intensity varied consider-
ably between different glands, even in the same patientVDR are shown in detail in Figure 4. Statistical analysis
[12]. Only four glands from each of two patients withshowed that the nodular areas had a significantly higher
secondary HPT were analyzed, and no detailed descrip-expression of all analyzed mRNAs (P  0.05). The
tion of the distribution in nodular glands was given. Go-higher levels in nodular areas were not due to an in-
gusev et al reported that the expression of both CaRcreased density of cells in the nodules because the num-
mRNA and protein was depressed in hyperplastic glandsber of nuclei per unit area was the same in the nodular
of secondary HPT [14]. With regard to CaR mRNAand internodular areas (results not shown).
expression, the visual impression by light microscopyThe expression of CAS was generally low with no
was that the decrease was, in some instances, more pro-apparent differences between nodular and internodular
nounced in the nodular areas than in surrounding areasareas, making identification of single nodules difficult.
of the four glands analyzed. However, this differenceOne of the glands investigated was not hyperplastic
was not found using image analysis [14]. CaR proteindue to uremia, but came from a young patient with hypo-
staining was often lower in the nodular areas of fivephosphatemic rickets. This gland did not differ in any
analyzed glands.respect from those of the uremic patients.
A recent short report by Akizawa et al analyzed the
hyperplastic glands of six patients [33]. Although no nu-
DISCUSSION meric values were given in that report, it was stated that
CaR protein expression was particularly depressed inThis study investigated the expression of CaR, CAS,
the nodular lesions compared with diffuse lesions. AVDR, and PTH mRNA in hyperplastic parathyroid
more profound reduction of CaR mRNA was demon-glands of patients with hypercalcemic secondary HPT.
strated in large nodular hyperplastic glands than in smallCaR, CAS, and VDR all take part in the intricate regula-
hyperplastic glands. The method used was Northern blottion of PTH synthesis and secretion and probably also
and Southern blot analysis after reverse transcriptase-in the proliferation of parathyroid cells in secondary
polymerase chain reaction (RT-PCR). Thus, no informa-HPT. Although we could only analyze a very few normal
tion could be obtained about the relationship betweenparathyroid biopsies, our results are in general agree-
the nodular and internodular areas.ment with previous studies demonstrating reduced levels
Akizawa et al also reported that the expression ofof CaR [12, 14], CAS [8], and VDR [23, 24, 26, 31, 33],
CaR protein was inversely correlated to cellular prolifer-mRNA or protein in these glands in comparison with
ation as indicated by proliferating cell nuclear antigennormal parathyroid glands. In addition, the present in-
vestigation reveals unexpected findings at the mRNA (PCNA) [33]. Similar findings were made in hyperplastic
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Fig. 4. Vitamin D receptor mRNA expression in nodular parathyroids. A comparison between the nodular () and internodular ( ) areas is shown.
parathyroid glands of uremic rats fed with a phosphate- tein expression is only a secondary phenomenon has to
be proven. Decreased expression of receptor moleculesrich diet [34], where CaR was decreased primarily in
areas of active cell proliferation as indicated with PCNA. is a general and unspecific finding in rapidly proliferating
cells.In line with that study, Yano et al recently reported a
correlation between Ki67-positive cell numbers and CaR The expression of CAS mRNA was markedly reduced
in the hyperplastic glands when compared with the nor-protein in secondary hyperplastic glands [31].
To summarize previous studies on the expression of mal parathyroid glands. This finding is similar to that in
sporadic adenomas where CAS mRNA expression wasCaR protein, it is evident that CaR protein expression
is reduced in secondary HPT compared with normal reduced to 25% of that in normal parathyroid biopsies
from the same patient [35].parathyroid glands. It also seems clear that CaR protein
is more reduced in nodular areas than in diffusely hyper- The first report on reduced VDR in uremic HPT was
by Korkor, who used a binding assay and could demon-plastic areas of nodular glands. The reports concerning
CaR mRNA on the other hand are ambiguous. In the strate significantly lower levels of VDR in hyperplastic
parathyroid glands from patients with chronic renal fail-present study, higher as well as lower expression of CaR
mRNA was seen in nodules of nodular glands. Mean ure than in glands from patients with transplanted kid-
neys, and especially in comparison with adenomas ofmRNA expression was slightly, but significantly higher
in the nodular than in the internodular areas. patients with primary HPT [23]. Reduced levels of VDR
protein as revealed by immunocytochemistry also haveOne possible explanation for the discrepancy between
the present findings of expression at the mRNA level been reported by other investigators [24, 26]. Fukuda et
al found that VDR distribution was highly heteroge-and previous histochemical findings at the protein level
may be a different post-transcriptional handling of the neous, with significantly lower levels in nodular than in
diffusely hyperplastic tissue [26]. No detailed descriptionreceptor proteins in the nodular areas. A shorter half-
life or else different processing of receptor protein in on the relationship between different nodules and in-
ternodular areas was given. However, small nodules inthe nodules may be responsible. Whether the reduced
expression of CaR protein is the driving force behind diffusely hyperplastic glands were reported to be virtu-
ally negative with regard to VDR protein. Yano et alhyperplasia in the nodules or whether the reduced pro-
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confirmed that VDR protein is decreased in parathyroid to humoral factors such as serum phosphate, calcium or
active vitamin D. In view of the homogenous expressionglands from secondary HPT, but did not demonstrate a
significant difference between nodular and diffuse hyper- within each nodule a genetic reason must be anticipated.
It is probable that the rapid proliferation caused by highplasia. In contrast, detailed analysis showed that nodular
areas did not show a decreased expression of VDR com- serum phosphate/low serum calcium/low vitamin D in-
creases the risk for genetic “mishappenings” that arepared with surrounding internodular areas [31]. Carling
et al analyzed VDR mRNA in secondary HPT using then inherited by all cells in a certain nodule. The nature
of these mutations is not known. No frequent large ge-RNase protection assay of whole glands and reported
low levels compared with normal parathyroid and sig- netic events (gains or losses) have been found using
comparative genomic hybridization of whole glands [38]nificantly lower levels in nodular than in diffusely hyper-
plastic tissue [25]. However, their results were all cor- and allelic losses are infrequent in single nodules [39].
Although one report has indicated a role for the MEN1rected for the level of GAPDH, which was used as an
internal standard. In view of the variation in the expres- region on chromosome 11q13 [40], this has not been veri-
fied as a common mechanism in other reports [38, 41].sion of GAPDH mRNA demonstrated in the present
investigation, caution should be taken when interpreting Our findings corroborate previous assumptions that each
nodule in secondary HPT is of monoclonal origin, butresults after such corrections, since they may distort the
results significantly. that the clonal origin of each nodule is separate [29].
The variation in the expression of receptor mRNAsAlso, the expression of PTH mRNA was reduced in
the hyperplastic glands when compared with the normal of importance for the control of PTH secretion and para-
thyroid proliferation gives an explanation to the greatparathyroid biopsies. This deviates from the findings in
experimentally induced secondary HPT of uremic ani- variability in size of each parathyroid gland in the same
patient. This finding also may explain the great variabilitymals in which the level of PTH mRNA is increased,
mainly due to decreased degradation of mRNA [36]. in the clinical course of secondary HPT, where some
patients can be adequately controlled by treatment withHowever, the present results are in agreement with hu-
man studies, where the PTH content in sporadic adeno- active vitamin D, while others are resistant to that treat-
ment.mas has been shown to be significantly lower than in
normal parathyroid glands even if no significant differ-
ences in mRNA levels could be detected [37]. The main ACKNOWLEDGMENTS
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